Finding the biomarkers of response to anti-VEGF treatment is today a priority of the research, according to Marc De Smet, MD, PhD. Response is widely variable, and biomarkers will help tailoring treatment options to the needs of individual patients.
Perspective: Marc De Smet, MD, PhD
Other Perspective
Home monitoring
Paolo Lanzetta, MD, interviews Anat Loewenstein, MD, on home monitoring, a technology in which her r
High-dose Aflibercept: the PHOTON and PULSAR trials
Paolo Lanzetta, MD, and Jean-François Korobelnik, MD, PhD, speak about high-dose Aflibercept and th
What is the current situation of ophthalmology in Ukraine?
Paolo Lanzetta, MD interviews Andrii Korol, MD about the situation of ophthalmology in Ukraine.
Office, ambulatory surgery room or operating theatre?
A study reviews evidence and provides recommendations for the ideal setting of intravitreal injectio
Related Articles
